Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Hims & Hers reached a commercial agreement with Novo Nordisk to sell Ozempic injections and Wegovy pills and will drop the lawsuit, removing a major legal overhang. Revenue grew 28% last quarter, and the stock trades at a forward P/E under ~20x for 2026 and below ~15x for 2027 based on consensus. The deal should drive revenue growth but at lower gross margins; Hims will still provide compound semaglutide when medically necessary but will not advertise it. Given the prior volatile relationship with Novo, investors should size positions conservatively despite the upside potential.

Analysis

Shifting a telehealth platform into low-margin branded drug distribution is a classic volume-for-margin trade. Expect near-term gross-margin compression (roughly several hundred basis points) while unit economics improve via higher order frequency and cross-sell opportunities; the breakpoint for EPS accretion will be whether incremental LTV / retention lifts enough to offset margin loss within 4–8 quarters.

Control of distribution by manufacturers changes the arbitrage landscape: compounding players and niche dispensaries lose pricing power, PBMs and specialty channels will recalibrate networks, and manufacturers gain leverage over price and supply timing. That increases predictability of supply (reducing stock-outs) but shifts working capital risk onto the platform — inventories and returns will matter more and can drive short-term cash volatility.

Key catalysts to watch in the next 6–12 months are: contribution margin per patient, sequential ARPU and retention, and any regulatory guidance that narrows compounding latitude. A favorable cadence of improving retention + predictable unit economics would validate a re-rating; conversely, either adverse regulatory action or margin pressure without retention improvement is the primary reversal mechanism.

The market is likely underweight the optionality embedded in customer data and cross-sell into higher-margin services (teletherapy, recurring care plans). That optionality is convex and realizable only if the platform maintains trust and low friction at point-of-sale — so position sizing should reflect binary regulatory/legal tails even as the base case upside is substantial over 12–24 months.

Key Decisions for Investors

• Initiate a tactical long HIMS position: 3% portfolio weight, horizon 12 months, target +35–50% upside if contribution margin per patient improves sequentially for two quarters. Hard stop at -18% to control regulatory/legal tail risk.
• Convex option play: buy HIMS Jan-2027 LEAP calls (≈30% OTM) sized to 0.8–1.0% of portfolio notional. This captures asymmetric upside from successful cross-sell adoption while limiting capital at risk; consider funding by selling 2–3 month covered calls to reduce net premium if short-term volatility is acceptable.
• Relative-value hedge: pair long HIMS (2–3% weight) with short NVO (1–2% weight) to express conviction that platform-level economics and data monetization can outperform manufacturer margin expansion. Hold 6–12 months; this reduces pure-category risk but accepts company-specific operational execution as the main driver.
• Tail protection: buy 3-month HIMS put spreads (10–15% OTM) sized to hedge 1–2% of portfolio against abrupt regulatory enforcement or litigation headlines. Cost-effective put spreads preserve upside while capping hedge cost.